Showing results (141-150 of 206) with videos related to
Sort By:
Pageof 21
European Journal of Haematology|May 19, 2010
Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOPDok Hyun Yoon, Dae Ro Choi, Heui June Ahn, et al.Journal of Clinical Apheresis|September 21, 2007
A randomized comparison of peripheral blood hematopoietic progenitor cell level of 5/mm3 versus 50/mm3 as a surrogate marker to initiate efficient autologous blood stem cell collectionMin Kyoung Kim, Shin Kim, Geundoo Jang, et al.Cancer Genetics|March 12, 2014
RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemiaJi-Hun Lim, Seongsoo Jang, Chan-Jeoung Park, et al.The Korean Journal of Hematology|April 6, 2012
A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomasJeong Eun Kim, Dok Hyun Yoon, Geundoo Jang, et al.Annals of Hematology|July 21, 2017
Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabineJae-Cheol Jo, Dok Hyun Yoon, Shin Kim, et al.Leukemia & Lymphoma|October 27, 2021
Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specifiedHyung-Don Kim, Hyungwoo Cho, Byeong Seok Sohn, et al.Leukemia & Lymphoma|June 27, 2009
Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in KoreaMyung Hee Chang, Seok Jin Kim, Kihyun Kim, et al.Leukemia & Lymphoma|April 16, 2020
The clinical outcomes of rituximab biosimilar CT-P10 (Truxima®) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experienceKyoungmin Lee, Joo Young Ha, Ah Ra Jung, et al.Oncotarget|September 24, 2017
The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myelomaJin Roh, Youkyoung Jeon, A-Neum Lee, et al.Histopathology|June 24, 2015
MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphomaJi-Young Choe, Ji Yun Yun, Hee Young Na, et al.Pageof 21